Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170] (The Lancet Regional Health - Europe (2025) 50, (S2666776224003399), (10.1016/j.lanepe.2024.101170))
Articolo
Data di Pubblicazione:
2025
Citazione:
Correction to “New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe” [The Lancet Regional Health – Europe, volume 50, March 2025, 101170] (The Lancet Regional Health - Europe (2025) 50, (S2666776224003399), (10.1016/j.lanepe.2024.101170)) / Rimassa, L.; Lamarca, A.; O'Kane, G. M.; Edeline, J.; Mcnamara, M. G.; Vogel, A.; Fassan, M.; Forner, A.; Kendall, T.; Adeva, J.; Casadei-Gardini, A.; Fornaro, L.; Hollebecque, A.; Lowery, M. A.; Macarulla, T.; Malka, D.; Mariamidze, E.; Niger, M.; Ustav, A.; Bridgewater, J.; Macias, R. I. R.; Braconi, C.. - In: THE LANCET REGIONAL HEALTH. EUROPE. - ISSN 2666-7762. - 53:(2025). [10.1016/j.lanepe.2025.101306]
Abstract:
The authors regret the mistake in Table 2: Targeted therapies for advanced biliary tract cancers: Median overall survival in the HERIZON-BTC-01 phase 2 trial of zanidatamab was 15.5 months in the HER2+ population, while the table shows 5.5 months. In the Lancet Oncology publication cited in the manuscript OS was not mature, and the OS of 15.5 months was reported at ASCO 2024.1 The authors would like to apologise for any inconvenience caused.
Tipologia CRIS:
1.1.5. Erratum
Elenco autori:
Rimassa, L.; Lamarca, A.; O'Kane, G. M.; Edeline, J.; Mcnamara, M. G.; Vogel, A.; Fassan, M.; Forner, A.; Kendall, T.; Adeva, J.; Casadei-Gardini, A.; Fornaro, L.; Hollebecque, A.; Lowery, M. A.; Macarulla, T.; Malka, D.; Mariamidze, E.; Niger, M.; Ustav, A.; Bridgewater, J.; Macias, R. I. R.; Braconi, C.
Link alla scheda completa:
Link al Full Text:
Pubblicato in: